Horizon Pharma (NASDAQ:HZNP) was upgraded by equities research analysts at TheStreet from a “c” rating to a “b-” rating in a research report issued on Tuesday.

Other equities research analysts have also issued reports about the company. Jefferies Financial Group raised their price target on Horizon Pharma from $21.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. Mizuho reissued a “buy” rating and set a $18.00 price target on shares of Horizon Pharma in a research note on Wednesday, August 8th. ValuEngine raised Horizon Pharma from a “hold” rating to a “buy” rating in a research note on Monday, July 30th. Cowen reissued a “buy” rating and set a $25.00 price target on shares of Horizon Pharma in a research note on Thursday, August 9th. Finally, Piper Jaffray Companies reissued a “buy” rating and set a $25.00 price target on shares of Horizon Pharma in a research note on Thursday, August 9th. Six investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Horizon Pharma presently has a consensus rating of “Buy” and an average target price of $23.25.

Shares of HZNP stock opened at $20.90 on Tuesday. Horizon Pharma has a 52-week low of $12.55 and a 52-week high of $23.38. The company has a debt-to-equity ratio of 2.06, a current ratio of 1.94 and a quick ratio of 1.86. The company has a market cap of $3.45 billion, a P/E ratio of 17.71, a price-to-earnings-growth ratio of 1.36 and a beta of 1.29.

Horizon Pharma (NASDAQ:HZNP) last issued its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.50 by $0.15. Horizon Pharma had a positive return on equity of 27.14% and a negative net margin of 18.70%. The firm had revenue of $325.30 million during the quarter, compared to analyst estimates of $311.84 million. During the same period last year, the company earned $0.26 EPS. Horizon Pharma’s quarterly revenue was up 19.8% compared to the same quarter last year. Research analysts expect that Horizon Pharma will post 1.3 EPS for the current year.

In other Horizon Pharma news, Chairman Timothy P. Walbert sold 408,347 shares of Horizon Pharma stock in a transaction on Wednesday, November 14th. The stock was sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the completion of the sale, the chairman now directly owns 650,404 shares of the company’s stock, valued at approximately $14,009,702.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 3.90% of the company’s stock.

Large investors have recently made changes to their positions in the company. First Quadrant L P CA increased its holdings in shares of Horizon Pharma by 189.1% in the 3rd quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock valued at $120,000 after acquiring an additional 4,001 shares during the period. Quantitative Systematic Strategies LLC purchased a new position in shares of Horizon Pharma in the 2nd quarter valued at $172,000. Strs Ohio increased its holdings in shares of Horizon Pharma by 74.2% in the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 4,600 shares during the period. Ibex Investors LLC purchased a new position in shares of Horizon Pharma in the 3rd quarter valued at $211,000. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Horizon Pharma in the 3rd quarter valued at $213,000. Institutional investors and hedge funds own 88.64% of the company’s stock.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

Further Reading: Cash Flow Analysis in Stock Selection

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.